Specialty Pharmacy

NCPA taps former GPhA chief Jaeger to succeed Bruce Roberts as next CEO
Assured sees high rise in same-store sales
Genentech's Herceptin receives FDA approval

SOUTH SAN FRANCISCO, Calif. The Food and Drug Administration has approved a biotech drug for treating cancer of the stomach and esophageal junction.

Genentech, a subsidiary of Swiss drug maker Roche, announced Wednesday the approval of Herceptin (trastuzumab) as a treatment for cancer of the stomach that includes the HER2 gene and has spread to other parts of the body, when combined with chemotherapy. The drug has long since had approval as a treatment for HER2-positive breast cancer.
Combining Invirase, Norvir could cause health problems
Transcript Pharmacy receives ACHC accreditation
Cardiovascular, diabetes risk associated with prostate cancer drug class

SILVER SPRING, Md. Patients taking a certain class of drugs mostly used for prostate cancer may be at higher risk of heart disease and diabetes, the Food and Drug Administration warned on Wednesday.
Diplomat takes employees back to school
NeurogesX seeks expanded approval for Qutenza

SAN MATEO, Calif. A company that develops drugs for pain is hoping to get approval of one of its drugs for a pain condition associated with HIV.

Strativa enters license, supply agreement with Sobi